In preclinical models of BC, CDK-i resistant cells showed a decreased ER expression and a reduced efficacy of anti-estrogen drugs, but a preserved sensitivity to the PI3K-inhibitor Alpelisib and the mTOR-inhibitor Everolimus (21). Here, MTOR is linked to breast cancer.